

neither an environmental assessment nor an environmental impact statement is required.

This rule does not meet the definition of "rule" in 5 U.S.C. 804(3)(A) because it is a rule of "particular applicability." Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808.

#### List of Subjects in 21 CFR Part 520

Animal drugs.

■ Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is amended as follows:

#### PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

■ 1. The authority citation for 21 CFR part 520 continues to read as follows:

**Authority:** 21 U.S.C. 360b.

■ 2. Add § 520.2130 to read as follows:

#### § 520.2130 Spinosad.

(a) *Specifications.* Each chewable tablet contains 140, 270, 560, 810, or 1620 milligrams (mg) spinosad.

(b) *Sponsor.* See No. 000986 in § 510.600 of this chapter.

(c) *Conditions of use in dogs—(1) Amount.* Administer tablets once a month at a recommended minimum dosage of 13.5 mg per pound (30 mg per kilogram) of body weight.

(2) *Indications for use.* To kill fleas and for the prevention and treatment of flea infestations (*Ctenocephalides felis*) on dogs for 1 month.

(3) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Dated: October 17, 2007.

**Bernadette Dunham,**

*Deputy Director, Center for Veterinary Medicine.*

[FR Doc. E7–21058 Filed 10–24–07; 8:45 am]

**BILLING CODE 4160–01–S**

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Food and Drug Administration

#### 21 CFR Parts 520 and 558

#### New Animal Drugs; Change of Sponsor

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a

change of sponsor for five approved new animal drug applications (NADAs) from Merial Ltd., to Huvepharma AD.

**DATES:** This rule is effective October 25, 2007.

#### FOR FURTHER INFORMATION CONTACT:

David R. Newkirk, Center for Veterinary Medicine (HFV–100), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–6967, e-mail: [david.newkirk@fda.hhs.gov](mailto:david.newkirk@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** Merial Ltd., 3239 Satellite Blvd., Bldg. 500, Duluth, GA 30096–4640 has informed FDA that it has transferred ownership of, and all rights and interest in, the following five approved NADAs to Huvepharma AD, 33 James Boucher Blvd., Sophia 1407, Bulgaria:

Application No.	Trade name(s)
012–350	AMPROVINE (amprolium) 25% Type A Medicated Article; CORID (amprolium) 25% Type A Medicated Article
013–149	AMPROVINE (amprolium) 9.6% Solution
013–461	Broiler PMX No. 1620 (amprolium/ethopabate)
033–165	AMPROVINE (amprolium) 20% Soluble Powder; CORID (amprolium) 20% Soluble Powder
034–393	COYDEN 25 (clopidol); Lerbek 25

Accordingly, the agency is amending the regulations in 21 CFR 520.100, 558.55, 558.58, and 558.175 to reflect the transfer of ownership.

This rule does not meet the definition of "rule" in 5 U.S.C. 804(3)(A) because it is a rule of "particular applicability." Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808.

#### List of Subjects

21 CFR Part 520

Animal drugs.

21 CFR Part 558

Animal drugs, Animal feeds.

■ Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 520 and 558 are amended as follows:

#### PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

■ 1. The authority citation for 21 CFR part 520 continues to read as follows:

**Authority:** 21 U.S.C. 360b.

#### § 520.100 [Amended]

■ 2. In paragraph (b)(1) of § 520.100, remove "050604" and in its place add "016592".

#### PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

■ 3. The authority citation for 21 CFR part 558 continues to read as follows:

**Authority:** 21 U.S.C. 360b, 371.

#### § 558.55 [Amended]

■ 4. In paragraph (a) of § 558.55, remove "050604" and in its place add "No. 016592".

■ 5. In § 558.58, in the table in paragraph (e)(1)(i), in the first entry, in the "Sponsor" column, add "050604" and "016592"; add paragraph (a)(3); and revise paragraph (b) to read as follows:

#### § 558.58 Amprolium and ethopabate.

(a) \* \* \*

(3) 25 percent amprolium and 0.8 percent ethopabate.

(b) *Approvals.* See § 510.600(c) of this chapter.

(1) No. 050604 for products described in paragraph (a) of this section.

(2) No. 016592 for product described in paragraph (a)(3) of this section.

#### § 558.175 [Amended]

■ 6. In § 558.175, in paragraph (b) and in the table in paragraph (d)(1) in the "Sponsor" column, remove "050604" and in its place add "016592".

Dated: October 17, 2007.

**Bernadette Dunham,**

*Deputy Director, Center for Veterinary Medicine.*

[FR Doc. E7–21057 Filed 10–24–07; 8:45 am]

**BILLING CODE 4160–01–S**

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Food and Drug Administration

#### 21 CFR Part 558

#### New Animal Drugs For Use in Animal Feeds; Change of Sponsor

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the

animal drug regulations to reflect a change of sponsor for seven approved new animal drug applications (NADAs) from Schering-Plough Animal Health Corp. to Huvepharma AD.

**DATES:** This rule is effective October 25, 2007.

**FOR FURTHER INFORMATION CONTACT:** David R. Newkirk, Center for Veterinary Medicine (HFV-100), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-6967, e-mail: *david.newkirk@fda.hhs.gov*.

**SUPPLEMENTARY INFORMATION:** Schering-Plough Animal Health Corp., 556 Morris

Ave., Summit NJ 07901, has informed FDA that it has transferred ownership of, and all rights and interest in, the following seven approved NADAs to Huvepharma AD, 33 James Boucher Blvd., Sophia 1407, Bulgaria:

Application No.	Trade name(s)
140-951	CLINICOX (diclazuril) Type A Medicated Article
141-090	CLINICOX / STAFAC
141-153	CLINICOX / BMD
141-158	CLINICOX / FLAVOMYCIN
141-190	CLINICOX / BMD / 3-NITRO
141-194	CLINICOX / BMD
141-195	CLINICOX / FLAVOMYCIN

Accordingly, the agency is amending the regulations in 21 CFR 558.198 to reflect the transfer of ownership.

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

**List of Subjects in 21 CFR Part 558**

Animal drugs, Animal feeds.

■ Therefore, under the Federal Food, Drug and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 558 is amended as follows:

**PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS**

■ 1. The authority citation for 21 CFR part 558 continues to read as follows:

**Authority:** 21 U.S.C. 360b, 371.

**§ 558.198 [Amended]**

■ 2. In § 558.198, in paragraph (b), remove “000061” and in its place add “016592”; and in the tables in paragraphs (d)(1) and (d)(2), in the “Sponsor” column, remove “000061” wherever it occurs and in its place add “016592”.

Dated: October 17, 2007.

**Bernadette Dunham,**  
Deputy Director, Center for Veterinary Medicine.

[FR Doc. E7-21059 Filed 10-24-07; 8:45 am]

**BILLING CODE 4160-01-S**

**DEPARTMENT OF THE TREASURY**

**Internal Revenue Service**

**26 CFR Part 1**

**[TD 9361]**

**RIN 1545-BD56**

**Corporate Reorganizations; Transfers of Assets or Stock Following a Reorganization**

**AGENCY:** Internal Revenue Service (IRS), Treasury.

**ACTION:** Final regulations.

**SUMMARY:** This document contains final regulations that provide guidance regarding the effect of certain transfers of assets or stock on the continuing qualification of transactions as reorganizations under section 368(a). This document also contains final regulations that provide guidance on the continuity of business enterprise requirement and the definitions of “qualified group” and “party to a reorganization.” These regulations affect corporations and their shareholders.

**DATES:** *Effective Date:* These regulations are effective October 25, 2007.

*Applicability Date:* For dates of applicability, see §§ 1.368-1(d)(4)(iv), 1.368-1(d)(5), 1.368-2(f), 1.368-2(j)(3)(iv), and 1.368-2(k)(3).

**FOR FURTHER INFORMATION CONTACT:** Mary W. Lyons, at (202) 622-7930 (not a toll free number).

**SUPPLEMENTARY INFORMATION:**

**Background**

On August 18, 2004, the IRS and Treasury Department published a notice

of proposed rulemaking (REG-130863-04) in the **Federal Register** (69 FR 51209) proposing regulations that would provide guidance regarding the effect of certain transfers of assets or stock on the qualification of a transaction as a reorganization under section 368(a) (the proposed regulations). The proposed regulations also included amendments to the continuity of business enterprise (COBE) regulations under § 1.368-1(d) and the definition of a “party to a reorganization” under § 1.368-2(f). The proposed regulations replaced an earlier proposal, dated March 2, 2004 (REG-165579-02) and published in the **Federal Register** (69 FR 9771), which was withdrawn. No public hearing regarding the proposed regulations was requested or held. However, a number of comments were received, the most significant of which are discussed in this preamble.

The theory underlying the tax-free treatment afforded reorganizations described in section 368 is that such transactions “effect only a readjustment of continuing interest in property under modified corporate forms.” See § 1.368-1(b). The continuity of interest and continuity of business enterprise requirements are expressions of this principle. Earlier cases also implemented this principle through a concept that later became known as the prohibition of “remote” continuity of interest. Commonly viewed as arising out of the Supreme Court decisions in *Groman v. Commissioner*, 302 U.S. 82 (1937), and *Helvering v. Bashford*, 302 U.S. 454 (1938), remote continuity of interest focuses on the link between the former target corporation (T)